Table 1.
General characteristics of study participants for treatment with ASAQ and AL by study site in Togo, 2012–2013
| Drug | Site | N | Male/female | Mean age, months (SD) | Mean temperature, °C (SD) | Geometric mean parasitaemia, µL−1 (95 % CI) |
|---|---|---|---|---|---|---|
| ASAQ | Lomé | 93 | 44/49 | 37.6 (16.2) | 39.1 (0.9) | 23,906 (2187–198,250) |
| ASAQ | Sokodé | 86 | 39/47 | 35.6 (15.1) | 38.8 (0.9) | 38,720 (2026–240,000) |
| ASAQ | Niamtougou | 83 | 48/35 | 37.8 (15.4) | 38.6 (1.0) | 34,242 (2226–235,000) |
| AL | Lomé | 90 | 49/41 | 36.6 (16.8) | 39.1 (0.9) | 29,986 (2076–215,786) |
| AL | Sokodé | 88 | 51/37 | 35.5 (16.5) | 38.8 (0.9) | 31,824 (2060–230,211) |
| AL | Niamtougou | 83 | 43/40 | 36.9 (15.3) | 38.5 (1.0) | 29,685 (2172–224,250) |